nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.05.2010 | Original Paper

Oroxylin A inhibits angiogenesis through blocking vascular endothelial growth factor-induced KDR/Flk-1 phosphorylation

verfasst von: Ying Gao, Na Lu, Yun Ling, Yan Chen, Ling Wang, Qing Zhao, Qi Qi, Wei Liu, Haiwei Zhang, Qidong You, Qinglong Guo

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In this study, we examined the antiangiogenic effect of oroxylin A in vitro and in vivo and explored the potential mechanisms for this effect.

Methods

Transwell assay and tube formation assay were used to evaluate the effects of oroxylin A on vascular endothelial growth factor (VEGF)-induced migration and tube formation of human umbilical vein endothelial cells (HUVECs). Rat aortic ring assay was also employed to assess the effect of oroxylin A on microvessel outgrowth from rat aorta. Human tumor xenografts model in nude mice was further used to investigate the antiangiogenic activity of oroxylin A in vivo. Western blot analysis was used to investigate the related mechanism.

Results

Oroxylin A remarkably suppressed the VEGF-stimulated migration and tube formation of HUVECs. It also inhibited microvessel sprouting from rat aortic ring in vitro. In addition, it suppressed the angiogenesis of xenograft tumor in nude mice, which concurred with the inhibition of tumor growth. Moreover, oroxylin A blocked VEGF-induced phosphorylation of KDR/Flk-1 and related downstream signaling molecules, including p38 mitogen-activated protein kinase, extracellular signal-regulated kinase and Akt.

Conclusion

Oroxylin A possessed antiangiogenic activities in vitro and in vivo, which could be an underlying mechanism of its anticancer effect.

Berger AC, Wang XQ, Zalatoris A et al (2004) A murine model of ex vivo angiogenesis using aortic disks grown in fibrin clot. Microvasc Res 68:179–187CrossRefPubMed

Blagosklonny MV (2004) Antiangiogenic therapy and tumor progression. Cancer Cell 5:13–17CrossRefPubMed

Cabebe E, Wakelee H (2007) Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol 8:15–27CrossRefPubMed

Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9:653–660CrossRefPubMed

Carnesecchi S, Bras-Goncalves R, Bradaia A et al (2004) Geraniol, a component of plant essential oils, modulates DNA synthesis and potentiates 5-fluorouracil efficacy on human colon tumor xenografts. Cancer Lett 215:53–59CrossRefPubMed

Colavitti R, Pani G, Bedogni B et al (2002) Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR. J Biol Chem 277:3101–3108CrossRefPubMed

Collins TS, Hurwitz HI (2005) Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. Semin Oncol 32:61–68CrossRefPubMed

Ellis LM, Takahashi Y, Liu W, Shaheen RM (2000) Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist 5(suppl 1):11–15CrossRefPubMed

Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15–18PubMed

Folkman J (2006) Angiogenesis. Annu Rev Med 57:1–18CrossRefPubMed

Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6:273–286CrossRefPubMed

Goodwin AM (2007) In vitro assays of angiogenesis for assessment of angiogenic and anti-angiogenic agents. Microvasc Res 74:172–183CrossRefPubMed

Hu Y, Yang Y, You QD et al (2006) Oroxylin A induced apoptosis of human hepatocellular carcinoma cell line HepG2 was involved in its antitumor activity. Biochem Biophys Res Commun 351:521–527CrossRefPubMed

Huang C, Jacobson K, Schaller MD (2004) MAP kinases and cell migration. J Cell Sci 117:4619–4628CrossRefPubMed

Jaffe EA, Nachman RL, Becker CG et al (1973) Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52:2745–2756CrossRefPubMed

Jiang BH, Liu LZ (2008) AKT signaling in regulating angiogenesis. Current Cancer Drug Targets 8:19–26CrossRefPubMed

Kakeji Y, Koga T, Sumiyoshi Y (2002) Clinical significance of vascular endothelial growth factor expression in gastric cancer. J Exp Clin Cancer Res 21:125–129PubMed

Kanno S, Oda N, Abe M et al (2000) Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 19:2138–2146CrossRefPubMed

Kitamura T, Asai N, Enomoto A et al (2008) Regulation of VEGF-mediated angiogenesis by the Akt/PKB substrate Girdin. Nat Cell Biol 10:329–337CrossRefPubMed

Li HB, Chen F (2005) Isolation and purification of baicalein, wogonin and oroxylin A from the medicinal plant Scutellaria baicalensis by high-speed counter-current chromatography. J Chromatogr A 1074:107–110CrossRefPubMed

Li HN, Nie FF, Liu W et al (2009) Apoptosis induction of oroxylin A in human cervical cancer HeLa cell line in vitro and in vivo. Toxicology 257:80–85CrossRefPubMed

Ling Y, Yang Y, Lu N et al (2007) Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 361:79–84CrossRefPubMed

Meyer RD, Rahimi (2003) Comparative structure-function analysis of VEGFR-1 and VEGFR-2: What have we learned from chimeric systems? Ann N Y Acad Sci 995:200–207CrossRefPubMed

Min JK, Han KY, Kim EC et al (2004) Capsaicin inhibits in vitro and in vivo angiogenesis. Cancer Res 64:644–651CrossRefPubMed

Nicosia RF, Bonanno E, Villaschi S (1992) Large-vessel endothelium switches to a microvascular phenotype during angiogenesis in collagen gel culture of rat aorta. Atherosclerosis 95:191–199CrossRefPubMed

Restucci B, De Vico G, Maiolino P (2000) Evaluation of angiogenesis in canine mammary tumors by quantitative platelet endothelial cell adhesion molecule immunohistochemistry. Vet Pathol 37:297–301CrossRefPubMed

Sathornsumetee S, Rich JN (2007) Antiangiogenic therapy in malignant glioma: promise and challenge. Curr Pharm Des 13:3545–3558CrossRefPubMed

Shibuya M (2006a) Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 39:469–478PubMed

Shibuya M (2006b) Vascular endothelial growth factor (VEGF)-receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E. Endothelium 13:63–69CrossRefPubMed

Sonoda M, Nishiyama T, Matsukawa Y et al (2004) Cytotoxic activities of flavonoids from two Scutellaria plants in Chinese medicine. J Ethnopharmacol 91:65–68CrossRefPubMed

Sun Y, Lu N, Ling Y et al (2009) Oroxylin A suppresses invasion through down-regulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells. Eur J Pharmacol 603:22–28CrossRefPubMed

Tian X, Song S, Wu J (2001) Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803. Biochem Biophys Res Commun 286:505–512CrossRefPubMed

Vermeulen PB, Gasparini G, Fox SB et al (1996) Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A:2474–2484CrossRefPubMed

Weidner N (1995) Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36:169–180CrossRefPubMed

Wu ZQ, Guo QL, You QD et al (2004) Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol Pharm Bull 27:1769–1774CrossRefPubMed

Yang Y, Hu Y, Gu HY et al (2008) Oroxylin A induces G2/M phase cell-cycle arrest via inhibiting Cdk7-mediated expression of Cdc2/p34 in human gastric carcinoma BGC-823 cells. J Pharm Pharmacol 60:1459–1463CrossRefPubMed

Titel: Oroxylin A inhibits angiogenesis through blocking vascular endothelial growth factor-induced KDR/Flk-1 phosphorylation
verfasst von: Ying Gao
Na Lu
Yun Ling
Yan Chen
Ling Wang
Qing Zhao
Qi Qi
Wei Liu
Haiwei Zhang
Qidong You
Qinglong Guo
Publikationsdatum: 01.05.2010
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 5/2010
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-009-0705-2

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Oroxylin A inhibits angiogenesis through blocking vascular endothelial growth factor-induced KDR/Flk-1 phosphorylation

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2010

Expression of X-linked inhibitor of apoptosis protein in human prostate cancer specimens with and without neo-adjuvant hormonal therapy

TNF superfamily gene polymorphism as prognostic factor in early breast cancer

Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies

The importance of −460 C/T and +405 G/C single nucleotide polymorphisms to the function of vascular endothelial growth factor A in colorectal cancer

Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved

Circulating IL-1β levels, polymorphisms of IL-1B, and risk of cervical cancer in Chinese women

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie